质子泵抑制药给药与不对称二甲基精氨酸相关性的临床探索性研究

Clinical exploratory research on the correlation between the proton pump inhibitors administration and the asymmetric dimethylarginine

目的探索质子泵抑制药(PPIs)药物暴露与不对称二甲基精氨酸(ADMA)体内水平动态变化之间的相关性。方法健康志愿者和十二指肠溃疡患者静脉输注艾普拉唑20 mg或埃索美拉唑40 mg,获取受试者的系列血浆样本并检测其中PPIs和ADMA浓度水平,以研究ADMA随PPIs给药的动态变化及两者之间的相互作用模式。结果健康志愿者(n=15)和十二指肠溃疡患者(n=20)的ADMA基线值分别为(0.44±0.05)和(0.53±0.09)μmol·L^(-1)。健康志愿者及患者血浆ADMA水平均未随PPIs浓度的改变发生显著波动,且两者不存在显著相关性(P>0.05)。结论 PPIs的使用并没有提高ADMA的水平,健康志愿者和患者的PPIs暴露与ADMA的水平之间均未展示出显著相关性。

Objective To elucidate the relationship between proton pump inhibitors(PPIs) exposure and asymmetric dimethylarginine(ADMA) kinetic elevation. Methods Healthy volunteers and patients with duodenal ulcer received intravenous infusion of ilaprazole 20 mg or esomeprazole 40 mg, and a series of plasma samples were collected. Plasma levels of ADMA and PPIs were detected synchronously to investigate the interactional pattern between PPIs and ADMA. Results The ADMA baseline were(0.44±0.05) μmol·L^(-1) in healthy volunteers(n=15) and(0.53±0.09) μmol·L^(-1) in patients with duodenal ulcer(n=20), respectively. Plasma ADMA levels in healthy volunteers and patients did not fluctuate significantly after PPIs administration. Furthermore, the plasma levels of ADMA were not statistically correlated with PPIs exposure(P>0.05).Conclusion The PPIs administration did not elevate the ADMA levels and there was no demonstrated relationship between PPIs exposure and ADMA levels in both healthy volunteers and patients.